Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 17.32 Billion KRW | -62.8% |
| 2022 | 46.44 Billion KRW | 40.15% |
| 2021 | 33.13 Billion KRW | 189.4% |
| 2020 | -37.06 Billion KRW | -244.3% |
| 2019 | 25.68 Billion KRW | -69.84% |
| 2018 | 85.17 Billion KRW | -0.83% |
| 2017 | 85.88 Billion KRW | 14.26% |
| 2016 | 75.17 Billion KRW | 45.51% |
| 2015 | 51.66 Billion KRW | 2.9% |
| 2014 | 50.2 Billion KRW | 199.62% |
| 2013 | 16.75 Billion KRW | -1.64% |
| 2012 | 17.03 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -929.98 Million KRW | -138.28% |
| 2024 Q2 | 14.33 Billion KRW | 1641.13% |
| 2023 Q2 | 9.55 Billion KRW | 440.42% |
| 2023 FY | 17.27 Billion KRW | -62.8% |
| 2023 Q4 | 2.42 Billion KRW | -32.03% |
| 2023 Q1 | 1.76 Billion KRW | -89.15% |
| 2023 Q3 | 3.57 Billion KRW | -62.58% |
| 2022 Q3 | 14.52 Billion KRW | 39.99% |
| 2022 FY | 46.44 Billion KRW | 40.15% |
| 2022 Q4 | 16.29 Billion KRW | 12.18% |
| 2022 Q2 | 10.37 Billion KRW | 89.76% |
| 2022 Q1 | 5.46 Billion KRW | 790.65% |
| 2021 FY | 33.13 Billion KRW | 189.4% |
| 2021 Q1 | -4.41 Billion KRW | 61.86% |
| 2021 Q2 | 4.43 Billion KRW | 200.57% |
| 2021 Q3 | 33.91 Billion KRW | 664.17% |
| 2021 Q4 | -791.73 Million KRW | -102.33% |
| 2020 Q3 | -11.44 Billion KRW | -177.57% |
| 2020 Q4 | -11.56 Billion KRW | -1.11% |
| 2020 FY | -37.06 Billion KRW | -244.3% |
| 2020 Q2 | -4.12 Billion KRW | 58.51% |
| 2020 Q1 | -9.93 Billion KRW | -113.99% |
| 2019 FY | 25.68 Billion KRW | -69.84% |
| 2019 Q1 | 15.77 Billion KRW | -7.04% |
| 2019 Q2 | 11.25 Billion KRW | -28.68% |
| 2019 Q4 | -4.64 Billion KRW | -240.71% |
| 2019 Q3 | 3.29 Billion KRW | -70.68% |
| 2018 Q4 | 16.97 Billion KRW | -9.65% |
| 2018 FY | 85.17 Billion KRW | -0.83% |
| 2018 Q3 | 18.78 Billion KRW | -15.48% |
| 2018 Q2 | 22.22 Billion KRW | -19.19% |
| 2018 Q1 | 27.5 Billion KRW | 22.31% |
| 2017 Q3 | 16.93 Billion KRW | -35.81% |
| 2017 Q1 | 21.18 Billion KRW | -4.04% |
| 2017 Q2 | 26.38 Billion KRW | 24.56% |
| 2017 Q4 | 22.48 Billion KRW | 32.77% |
| 2017 FY | 85.88 Billion KRW | 14.26% |
| 2016 Q4 | 22.07 Billion KRW | 23.8% |
| 2016 Q3 | 17.83 Billion KRW | -5.31% |
| 2016 Q2 | 18.83 Billion KRW | 14.56% |
| 2016 Q1 | 16.43 Billion KRW | 17.38% |
| 2016 FY | 75.17 Billion KRW | 45.51% |
| 2015 Q2 | 14.03 Billion KRW | 26.28% |
| 2015 Q1 | 11.11 Billion KRW | 69.09% |
| 2015 Q4 | 14 Billion KRW | 12.0% |
| 2015 Q3 | 12.5 Billion KRW | -10.93% |
| 2015 FY | 51.66 Billion KRW | 2.9% |
| 2014 Q1 | 7.55 Billion KRW | 83.14% |
| 2014 Q4 | 6.57 Billion KRW | -75.2% |
| 2014 Q2 | 9.56 Billion KRW | 26.67% |
| 2014 Q3 | 26.5 Billion KRW | 176.97% |
| 2014 FY | 50.2 Billion KRW | 199.62% |
| 2013 Q2 | 5.43 Billion KRW | 74.14% |
| 2013 Q4 | 4.12 Billion KRW | 1.37% |
| 2013 FY | 16.75 Billion KRW | -1.64% |
| 2013 Q1 | 3.12 Billion KRW | -0.24% |
| 2013 Q3 | 4.06 Billion KRW | -25.17% |
| 2012 FY | 17.03 Billion KRW | 0.0% |
| 2012 Q4 | 3.13 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 113.855% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 627.322% |
| BINEX Co., Ltd. | 1.04 Billion KRW | -1561.992% |
| Bioneer Corporation | 791.75 Million KRW | -2087.846% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 441.405% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 168.929% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 156.036% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 149.148% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 283.788% |
| Peptron, Inc. | -15.6 Billion KRW | 211.02% |
| Amicogen, Inc. | 2.05 Billion KRW | -742.468% |
| Genexine, Inc. | -41.24 Billion KRW | 142.003% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 299.101% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 121.433% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 277.905% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 82.818% |
| SillaJen, Inc. | -21.34 Billion KRW | 181.151% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | -557.734% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 195.254% |
| Genomictree Inc. | -17.3 Billion KRW | 200.109% |
| MedPacto, Inc. | -28.75 Billion KRW | 160.247% |
| D&D Pharmatech | -13.48 Billion KRW | 228.444% |
| EASY BIO,Inc. | 20.63 Billion KRW | 16.038% |
| GI Innovation, Inc. | -55.6 Billion KRW | 131.153% |